NEXALIN TECHNOLOGY INC. - COMMON STOCK

0.8419

26-August-25 08:14:12

15 minutes delayed

Stocks

+0.0079

+0.95%

Today's range

0.8110 - 0.8600

ISIN

N/A

Source

NASDAQ

Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025

14 Jan 2025 05:30:00 By Nasdaq GlobeNewswire
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

23 Dec 2024 07:00:00 By Nasdaq GlobeNewswire
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

26 Nov 2024 07:00:00 By Nasdaq GlobeNewswire
Nexalin Technology CEO Provides Letter to Shareholders

11 Nov 2024 05:00:00 By Nasdaq GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th

01 Nov 2024 11:00:00 By Nasdaq GlobeNewswire
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

01 Nov 2024 07:34:54 By Nasdaq GlobeNewswire
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

28 Oct 2024 05:30:00 By Nasdaq GlobeNewswire
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

22 Oct 2024 11:15:00 By Nasdaq GlobeNewswire
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients

17 Oct 2024 05:30:00 By Nasdaq GlobeNewswire
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

14 Oct 2024 05:30:00 By Nasdaq GlobeNewswire
Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

05 Sep 2024 06:00:00 By Nasdaq GlobeNewswire
Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

18 Jul 2024 05:30:00 By Nasdaq GlobeNewswire
Nexalin Technology Announces Closing of $5.2 Million Public Offering

01 Jul 2024 11:45:00 By Nasdaq GlobeNewswire
Nexalin Technology Announces Pricing of $5.2 Million Public Offering

27 Jun 2024 18:15:00 By Nasdaq GlobeNewswire
Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal

26 Jun 2024 06:00:00 By Nasdaq GlobeNewswire
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

20 Jun 2024 05:30:00 By Nasdaq GlobeNewswire
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

13 Jun 2024 12:00:00 By Nasdaq GlobeNewswire
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th

04 Jun 2024 05:30:00 By Nasdaq GlobeNewswire
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

03 Jun 2024 05:30:00 By Nasdaq GlobeNewswire
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

22 May 2024 05:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.